Aagami Case Study - Assessment of Global Net Present Value (NPV) of a revolutionary Nanotechnology Based Diagnostic Platform
Upcoming SlideShare
Loading in...5
×
 

Aagami Case Study - Assessment of Global Net Present Value (NPV) of a revolutionary Nanotechnology Based Diagnostic Platform

on

  • 89 views

 

Statistics

Views

Total Views
89
Views on SlideShare
79
Embed Views
10

Actions

Likes
0
Downloads
0
Comments
0

2 Embeds 10

http://aagami.com 9
http://www.aagami.com 1

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Aagami Case Study - Assessment of Global Net Present Value (NPV) of a revolutionary Nanotechnology Based Diagnostic Platform Aagami Case Study - Assessment of Global Net Present Value (NPV) of a revolutionary Nanotechnology Based Diagnostic Platform Presentation Transcript

  • Case Study Client Client Need Solution Approach Results **Data has been sanitized and meant for Illustrative purposes only Global NPV of Technology (in USD Million) (P) Pessimistic Scenario Discount rate 8.60% Year 2012 2013 2014 2015 2016 2017 2018 Time 0 1 2 3 4 5 6 Revenue from Sale of NPTP POC devices - - 20.30 23.62 32.06 40.80 24.93 Revenue from Sale of Treated Cuvette - - 450.00 614.87 815.48 1,021.15 657.19 Total Cost of NPTP POC devices - - 4.10 5.66 7.69 9.78 5.98 Total Cost of Treated Cuvettes - - 175.00 387.88 514.43 644.17 414.57 Commercialisation Costs 400.00 - - - - - - Total Cash Inflow - - 470.30 638.49 847.54 1,061.96 682.11 Total cash Outflow 400.00 - 179.10 393.54 522.12 653.96 420.55 Net Cash Flow -400.00 - 291.20 244.95 325.43 408.00 261.56 Discount Factor 1.00 0.92 0.85 0.78 0.72 0.66 0.61 Discounted Cash Flow -400.00 - 246.91 191.24 233.96 270.09 159.44 NPV 1,524.77  Client wanted to commercialize ground breaking technology in the MI Diagnostics field, and wanted to know its commercial potential so that suitable licensing fees and model could be determined and also value could be showcased to Licensees Investors Controlled Innovative technology company  Aagami involved a team of a senior consultant part time and a business analyst full time to conduct primary and secondary research involving domain specialists to capture current market scenario.  Performed competitive benchmarking to assess a Relative Cost Benefit Index used later for determining technology platform (product) pricing.  Projected annual demand for next ten years in three different scenarios - Median, Optimistic and Pessimistic across multiple disease categories.  Forecasted Global Average Selling Price (ASP) and Cost associated with capex and opex  Validated commercializing options and measured incremental financial scenario for potential licensees  Determined the Global Net Present Value (NPV) and created Financial models  NPV of the technology and indicative licensing fees, along with several insights generated, served as conclusive guidance to the client for deal-making and negotiations.  The client was delighted which also resulted in repeat assignments